<DOC>
	<DOCNO>NCT00368914</DOCNO>
	<brief_summary>RATIONALE : Sirolimus may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose sirolimus treat patient metastatic unresectable solid tumor .</brief_summary>
	<brief_title>Sirolimus Treating Patients With Metastatic Unresectable Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pharmacodynamic optimal dose sirolimus , evaluate p70^s6 kinase inhibition peripheral blood mononuclear cell ( PBMC ) normal skin , patient metastatic unresectable solid tumor . - Correlate target inhibition tumor tissue PBMC normal skin target inhibition patient whose tumor amenable sequential tumor biopsy . Secondary - Characterize pharmacokinetics sirolimus patient - Determine pharmacodynamic effect sirolimus tumor , normal skin , normal oral mucosa patient - Correlate pharmacodynamic effect sirolimus pharmacokinetics clinical effect . - Correlate Akt signal pathway pharmacodynamic endpoint . - Explore pharmacokinetic-pharmacodynamic toxicodynamic relationship sirolimus patient . - Quantify toxicity sirolimus patient . - Evaluate , preliminarily , activity sirolimus patient . OUTLINE : This prospective , dose-escalation study . Patients receive oral sirolimus daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos sirolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . The pharmacodynamic optimal dose consider dose 10 patient treat without require dose escalation . Patients undergo blood collection , tumor tissue normal skin biopsy , oral mucosal smear periodically pharmacodynamic , pharmacokinetic , biomarker correlative study . After completion study treatment , patient follow 4 week . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor malignancy Metastatic inoperable disease Failed curative standard palliative therapy OR therapy exist Evaluable measurable disease Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Tumor amenable serial biopsy No known brain metastasis PATIENT CHARACTERISTICS : ECOG 01 Life expectancy ≥ 3 month WBC &gt; 3,500/mm³ Absolute neutrophil count &gt; 1,500/mm³ Hemoglobin &gt; 9 g/dL Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 2 mg/dL ALT AST ≤ 5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 5 time ULN Triglycerides &lt; 2 time ULN Total cholesterol &lt; 2 time ULN Willing undergo serial tumor biopsy normal skin biopsy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No immunodeficiency No gastrointestinal tract disease result inability take oral medication No requirement IV alimentation No active peptic ulcer disease No active infection No uncontrolled medical condition could potentially increase risk toxicity complication therapy No concurrent second malignancy within past 5 year No clinically significant cardiovascular disease , include follow : Myocardial infarction within past 12 month Unstable angina Peripheral vascular disease ≥ grade 2 Uncontrolled congestive heart failure Uncontrolled hypertension ( i.e. , systolic blood pressure [ BP ] &gt; 170 mm Hg , diastolic BP &gt; 95 mm Hg ) PRIOR CONCURRENT THERAPY : Recovered prior anticancer therapy No unresolved chronic toxicity &gt; CTC grade 2 No prior surgical procedure affect absorption More 4 week since prior surgery except minor procedure ( e.g. , dental work skin biopsy ) More 1 month since prior participation investigational drug trial More 1 month since prior chemotherapy No concurrent use follow : Phenytoin Carbamazepine Barbiturates Rifampin Phenobarbital Cyclosporine Clarithromycin Diltiazen Clotrimazole Ketoconazole Fluconazole Hypericum perforatum ( St. John 's wort ) Cimetidine Grapefruit juice No concurrent immunosuppressants No concurrent investigational commercial agent therapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>